Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry, Researchers Pan Study Showing Antioxidants May Up Mortality Risk

This article was originally published in The Tan Sheet

Executive Summary

Trade groups and researchers say faulty methodology was used in a meta-analysis concluding that antioxidant supplements may increase mortality risk

You may also be interested in...



Firms Sift Eye Study Data For Benefit From Lutein And Zeaxanthin

After the Age-Related Eye Disease Study found lutein, zeaxanthin and omega-3s do not slow age-related macular degeneration, supplement firms revisit the data and find lutein and zeaxanthin could slow the disease in deficient populations.

Firms Sift Eye Study Data For Benefit From Lutein And Zeaxanthin

After the Age-Related Eye Disease Study found lutein, zeaxanthin and omega-3s do not slow age-related macular degeneration, supplement firms revisit the data and find lutein and zeaxanthin could slow the disease in deficient populations.

FDA Keeps Door Open To Help Observational Studies Work For Health Claims

FDA says in a final guidance that observational studies alone are insufficient support for health claims, but the agency also says it is interested in making it easier for those studies to support claims

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel